Harvard Bioscience, Inc. (HBIO): Price and Financial Metrics


Harvard Bioscience, Inc. (HBIO): $3.75

-0.04 (-1.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HBIO POWR Grades


  • Value is the dimension where HBIO ranks best; there it ranks ahead of 82.77% of US stocks.
  • The strongest trend for HBIO is in Stability, which has been heading up over the past 179 days.
  • HBIO ranks lowest in Momentum; there it ranks in the 19th percentile.

HBIO Stock Summary

  • With a one year PEG ratio of 565.76, Harvard Bioscience Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.92% of US stocks.
  • The price/operating cash flow metric for Harvard Bioscience Inc is higher than 97.7% of stocks in our set with a positive cash flow.
  • In terms of twelve month growth in earnings before interest and taxes, Harvard Bioscience Inc is reporting a growth rate of -156.89%; that's higher than merely 12.14% of US stocks.
  • Stocks that are quantitatively similar to HBIO, based on their financial statements, market capitalization, and price volatility, are VERX, GLBE, CSPI, REFR, and MYGN.
  • Visit HBIO's SEC page to see the company's official filings. To visit the company's web site, go to www.harvardbioscience.com.

HBIO Valuation Summary

  • In comparison to the median Healthcare stock, HBIO's price/sales ratio is 73.57% lower, now standing at 3.
  • HBIO's EV/EBIT ratio has moved down 1985.8 over the prior 243 months.
  • Over the past 243 months, HBIO's price/sales ratio has gone down 8.7.

Below are key valuation metrics over time for HBIO.

Stock Date P/S P/B P/E EV/EBIT
HBIO 2021-08-31 3 4.3 -120.6 -1992.7
HBIO 2021-08-30 3 4.3 -120.6 -1992.7
HBIO 2021-08-27 3 4.2 -119.4 -1975.5
HBIO 2021-08-26 3 4.2 -118.8 -1967.2
HBIO 2021-08-25 3 4.3 -120.3 -1988.5
HBIO 2021-08-24 3 4.3 -120.5 -1990.6

HBIO Growth Metrics

    Its 4 year price growth rate is now at -11.78%.
  • Its year over year cash and equivalents growth rate is now at -1.14%.
  • The year over year revenue growth rate now stands at -5.75%.
Over the past 15 months, HBIO's revenue has gone up $16,816,000.

The table below shows HBIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 118.904 1.262 -0.288
2021-09-30 116.833 3.635 -1.864
2021-06-30 111.207 5.892 -2.792
2021-03-31 105.318 7.497 -3.963
2020-12-31 102.1 9.331 -7.81
2020-12-31 102.1 9.331 -7.81

HBIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HBIO has a Quality Grade of C, ranking ahead of 42.11% of graded US stocks.
  • HBIO's asset turnover comes in at 0.728 -- ranking 27th of 75 Measuring and Control Equipment stocks.
  • CAMT, NVMI, and ITRI are the stocks whose asset turnover ratios are most correlated with HBIO.

The table below shows HBIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.728 0.566 -0.002
2021-03-31 0.693 0.574 0.005
2020-12-31 0.666 0.568 -0.027
2020-12-31 0.666 0.568 -0.027
2020-09-30 0.657 0.564 -0.018
2020-06-30 0.665 0.560 -0.029

HBIO Price Target

For more insight on analysts targets of HBIO, see our HBIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.38 (Strong Buy)

HBIO Stock Price Chart Interactive Chart >

Price chart for HBIO

HBIO Price/Volume Stats

Current price $3.75 52-week high $8.75
Prev. close $3.79 52-week low $3.36
Day low $3.65 Volume 148,600
Day high $3.81 Avg. volume 182,411
50-day MA $5.26 Dividend yield N/A
200-day MA $6.49 Market Cap 154.65M

Harvard Bioscience, Inc. (HBIO) Company Bio


Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. The company was founded in 1901 and is based in Holliston, Massachusetts.


HBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

HBIO Latest Social Stream


Loading social stream, please wait...

View Full HBIO Social Stream

Latest HBIO News From Around the Web

Below are the latest news stories about Harvard Bioscience Inc that investors may wish to consider to help them evaluate HBIO as an investment opportunity.

Harvard Bioscience Schedules Fourth Quarter 2021 Earnings Conference Call for March 8, 2022 at 8:00 AM ET

HOLLISTON, Mass., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2021 before the market opens on March 8, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID #1749525. The conference call

Yahoo | February 21, 2022

Do Institutions Own Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares?

A look at the shareholders of Harvard Bioscience, Inc. ( NASDAQ:HBIO ) can tell us which group is most powerful...

Yahoo | February 18, 2022

Monarch Partners Asset Management LLC Buys Belden Inc, Xenia Hotels & Resorts Inc, Wintrust ...

Boston, MA, based Investment company Monarch Partners Asset Management LLC (Current Portfolio) buys Belden Inc, Xenia Hotels & Resorts Inc, Wintrust Financial Corp, WNS (Holdings), Meritage Homes Corp, sells PacWest Bancorp, Gates Industrial Corp PLC, Camping World Holdings Inc, Civitas Resources Inc, Civitas Resources Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Monarch Partners Asset Management LLC.

Yahoo | February 3, 2022

Strs Ohio Has $679,000 Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Strs Ohio cut its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 7.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 97,400 shares of the medical instruments suppliers stock after selling 8,100 shares during the quarter. Strs Ohios holdings in Harvard Bioscience were worth $679,000 at the end of the most recent reporting period. []

Dakota Financial News | December 23, 2021

Harvard Bioscience (NASDAQ:HBIO) shareholders have earned a 20% CAGR over the last five years

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Yahoo | December 20, 2021

Read More 'HBIO' Stories Here

HBIO Price Returns

1-mo -33.51%
3-mo -27.88%
6-mo -45.65%
1-year -45.97%
3-year 62.34%
5-year 59.57%
YTD -46.81%
2021 64.34%
2020 40.66%
2019 -4.09%
2018 -3.64%
2017 8.20%

Continue Researching HBIO

Want to see what other sources are saying about Harvard Bioscience Inc's financials and stock price? Try the links below:

Harvard Bioscience Inc (HBIO) Stock Price | Nasdaq
Harvard Bioscience Inc (HBIO) Stock Quote, History and News - Yahoo Finance
Harvard Bioscience Inc (HBIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7609 seconds.